These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10424739)

  • 1. Oral topotecan: bioavailablity and effect of food co-administration.
    Herben VM; Rosing H; ten Bokkel Huinink WW; van Zomeren DM; Batchelor D; Doyle E; Beusenberg FD; Beijnen JH; Schellens JH
    Br J Cancer; 1999 Jul; 80(9):1380-6. PubMed ID: 10424739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary and fecal excretion of topotecan in patients with malignant solid tumours.
    Herben VM; Schoemaker nE; Rosing H; van Zomeren DM; ten Bokkel Huinink WW; Dubbelman R; Hearn S; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):59-64. PubMed ID: 12111113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
    Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
    Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
    Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.
    Daw NC; Santana VM; Iacono LC; Furman WL; Hawkins DR; Houghton PJ; Panetta JC; Gajjar AJ; Stewart CF
    J Clin Oncol; 2004 Mar; 22(5):829-37. PubMed ID: 14990638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
    Zackrisson AL; Malmström H; Peterson C
    Eur J Clin Pharmacol; 2002 May; 58(2):103-8. PubMed ID: 12012141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors.
    Zamboni WC; Bowman LC; Tan M; Santana VM; Houghton PJ; Meyer WH; Pratt CB; Heideman RL; Gajjar AJ; Pappo AS; Stewart CF
    Cancer Chemother Pharmacol; 1999; 43(6):454-60. PubMed ID: 10321504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
    Guivarc'h PH; Vachon MG; Fordyce D
    Clin Ther; 2004 Sep; 26(9):1456-69. PubMed ID: 15531008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
    Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
    Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
    Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
    Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
    Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R
    Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
    Peters GJ; Noordhuis P; Van Groeningen CJ; Giaccone G; Holwerda U; Voorn D; Schrijvers A; Schornagel JH; Beijnen JH; Fumoleau P; Schellens JH
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4072-6. PubMed ID: 15217941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
    Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers.
    Delrat P; Paraire M; Jochemsen R
    Biopharm Drug Dispos; 2002 May; 23(4):151-7. PubMed ID: 12015789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
    Gronlund B; Hansen HH; Høgdall C; Engelholm SA
    Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of food effect on the extent of alprazolam absorption from an orally disintegrating tablet.
    Erdman K; Stypinski D; Combs M; Witt P; Stiles M; Pollock S
    Pharmacotherapy; 2007 Aug; 27(8):1120-4. PubMed ID: 17655512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The relative bioavailability and pharmacokinetics of chloral hydrate and its metabolites].
    Zimmermann T; Wehling M; Schulz HU
    Arzneimittelforschung; 1998 Jan; 48(1):5-12. PubMed ID: 9522024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Morrissey LH; Scullin DC; Houston GA; Prasthofer EF; Gray JR; Burris HA; Greco FA
    Cancer; 2002 May; 94(9):2426-33. PubMed ID: 12033195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.